Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
---|---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-157 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.000213 | uM | 7496.098 | 0.9527 | 0.8955 | 0.9037 | |
MDA-MB-157 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.00107 | uM | 7496.098 | 0.9809 | 0.9578 | 0.9037 | |
MDA-MB-157 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.00533 | uM | 7496.098 | 1.0075 | 1.0165 | 0.9037 | |
MDA-MB-157 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.0267 | uM | 7496.098 | 0.9985 | 0.9968 | 0.9037 | |
MDA-MB-157 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.133 | uM | 7496.098 | 0.9571 | 0.9053 | 0.9037 | |
MDA-MB-157 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.667 | uM | 7496.098 | 1.0066 | 1.0146 | 0.9037 | |
MDA-MB-157 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 3.33 | uM | 7496.098 | 0.9933 | 0.9851 | 0.9037 | |
MDA-MB-157 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 16.7 | uM | 7496.098 | 0.8871 | 0.7518 | 0.9037 | |
MDA-MB-157 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.0000427 | uM | 7498.098 | 1.0315 | 1.0569 | 1.1057 | |
MDA-MB-157 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.000213 | uM | 7498.098 | 0.9931 | 0.9876 | 1.1057 | |
MDA-MB-157 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.00107 | uM | 7498.098 | 1.0141 | 1.0254 | 1.1057 | |
MDA-MB-157 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.00533 | uM | 7498.098 | 1.0103 | 1.0187 | 1.1057 | |
MDA-MB-157 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.0267 | uM | 7498.098 | 1.0488 | 1.0880 | 1.1057 | |
MDA-MB-157 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.133 | uM | 7498.098 | 0.9683 | 0.9426 | 1.1057 | |
MDA-MB-157 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.667 | uM | 7498.098 | 0.9814 | 0.9663 | 1.1057 | |
MDA-MB-157 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 3.33 | uM | 7498.098 | 0.9683 | 0.9426 | 1.1057 | |
MDA-MB-157 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 16.7 | uM | 7498.098 | 0.9297 | 0.8724 | 1.1057 | |
MDA-MB-175-VII | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.0000427 | uM | 7499.098 | 1.0416 | 1.1312 | 0.6421 | |
MDA-MB-175-VII | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.000213 | uM | 7499.098 | 1.0198 | 1.0621 | 0.6421 | |
MDA-MB-175-VII | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.00107 | uM | 7499.098 | 1.0839 | 1.2674 | 0.6421 | |
MDA-MB-175-VII | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.00533 | uM | 7499.098 | 1.0704 | 1.2237 | 0.6421 | |
MDA-MB-175-VII | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.0267 | uM | 7499.098 | 1.0168 | 1.0527 | 0.6421 | |
MDA-MB-175-VII | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.133 | uM | 7499.098 | 1.0394 | 1.1241 | 0.6421 | |
MDA-MB-175-VII | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.667 | uM | 7499.098 | 0.9289 | 0.7831 | 0.6421 | |
MDA-MB-175-VII | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 3.33 | uM | 7499.098 | 0.6291 | -0.0283 | 0.6421 |